Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held by 12 shareholders into H shares.

The H-share full-circulation plan, approved at the 22 December 2025 extraordinary general meeting, was filed with the China Securities Regulatory Commission (CSRC) on 23 December 2025. Jiuyuan Gene anticipates receiving the CSRC’s filing notice by end-April 2026. Subject to regulatory review, all conversion procedures are slated for completion within the second quarter of 2026.

Assuming no other changes in the shareholdings of core connected persons, the conversion is expected to lift the company’s public float to approximately 31.13%, restoring compliance with Hong Kong’s minimum free-float requirement.

Management has committed to providing monthly updates on the restoration process and will release further announcements upon material developments. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.